Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
USRC Kidney Research
With
Akebia Therapeutics
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients greater than or equal to 18 years of age.
Receiving outpatient in-center hemodialysis at least three times per week for end-stage kidney disease.
Currently prescribed or eligible for erythropoiesis-stimulating agent based on approved facility policy
Understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure.
You may not be if
Contraindication to receive vadadustat or any of its known constituents per USPI.
Cirrhosis or active, acute liver disease. Concomitant use of any hypoxia-inducible factor prolyl-hydroxylases or OAT1/OAT3 inhibitors (probenacid, rifampicin, gemfibrozil, or teriflunomide).
Unable to comply with study requirements or in the opinion of a healthcare provider or a member of the central study team, not clinically stable to participate in the study.
Pregnant at time of consent (per subject self-report).
Clareo Health | Vafseo Outcomes In-Center Experience
